Terns Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TERN research report →
Range $53 – $53
Price Chart
About the company
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity.
- CEO
- Amy L. Burroughs
- IPO
- 2021
- Employees
- 59
- HQ
- Foster City, CA, US
Get TickerSpark's AI analysis on TERN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.77B
- P/E
- -51.41
- PEG
- -5.51
- P/S
- 0.00
- P/B
- 4.90
- EV/EBITDA
- -40.01
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -20.02%
- ROIC
- -10.91%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-110,124,000
- Net Income
- $-96,207,000-8.3%
- EPS
- $-1.03+8.0%
- OCF Growth
- -17.4%
- FCF Growth
- -17.3%
- 52W High
- $53.19
- 52W Low
- $2.65
- 50D MA
- $50.15
- 200D MA
- $29.48
- Beta
- -0.38
- RSI (14)
- 74
- Avg Volume
- 5.92M
No earnings-call transcripts are available for TERN yet.
- Free Float
- 99.7%
- Shares Outstanding
- 90.08M
- Float Shares
- 89.83M
of shares held by institutions
256 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 5.52M | ▲ 964.03K |
| Capitolis Liquid Global Markets LLC | 3.05M | ▲ 3.05M |
| Janus Henderson Group PLC | 1.47M | ▼ 1.91M |
| Absolute Gestao De Investimentos Ltda. | 230.00K | ▲ 230.00K |
| Cibra Capital Ltd | 151.44K | ▲ 151.44K |
| Groupe La Francaise | 118.45K | ▲ 118.45K |
| California State Teachers Retirement System | 70.22K | ▲ 64.94K |
| Cibc World Markets Corp | 5.67K | ▲ 5.67K |
| Cibc Private Wealth Group, LLC | 5.00K | 0 |
| Cwm, LLC | 4.17K | ▲ 1.38K |
| Quest Partners LLC | 1.01K | ▼ 89.88K |
| Comerica Bank | 105 | ▲ 105 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 5, 26 | Azelby Robert | sell | 90,000 |
| May 5, 26 | Azelby Robert | sell | 1,697 |
| May 5, 26 | Turner Heather D | sell | 45,000 |
| May 5, 26 | Turner Heather D | sell | 64,000 |
| May 5, 26 | Turner Heather D | sell | 1,697 |
| May 5, 26 | Tripuraneni Radhika | sell | 64,000 |
| May 5, 26 | Tripuraneni Radhika | sell | 45,000 |
| May 5, 26 | Tripuraneni Radhika | sell | 10,657 |
| May 5, 26 | Tripuraneni Radhika | sell | 4,676 |
| May 5, 26 | Tripuraneni Radhika | sell | 32,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TERN coverage
Recent articles, reports, and earnings notes.
No research on TERN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TERN report →Tern shares surge as it ups stakes in AI health services company Talking Medicines
proactiveinvestors.co.uk · May 26
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
businesswire.com · May 5
Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent Loss
seekingalpha.com · May 3
Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?
zacks.com · Apr 27
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
globenewswire.com · Apr 27
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
businesswire.com · Apr 24
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?
prnewswire.com · Apr 15
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
businesswire.com · Apr 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.